

# MediKredit NAPPI Changes and Information

Circular Number: N026/2019  
Circular Date: 15 October 2019  
Effective Date: 15 October 2019



## Important Notice

The below Section 21 product has now been registered. As per NAPPI policy, the section 21 NAPPI code will be retained for the registered product. Refer to the table below for the change in NAPPI description as a result of the product registration.

### DETAIL TABLE

SUPPLIER	NAPPI CODE	OLD PRODUCT DESCRIPTION	NEW PRODUCT DESCRIPTION
Novartis South Africa (Pty) Ltd	3000628001	Tafinlar (section 21) 75 mg	Tafinlar 75 mg

Should you require any further information about this change, please contact the supplier directly.

MediKredit Integrated Healthcare Solutions (Pty) Ltd

**Head Office:**  
**Johannesburg**  
10 Kikuyu Road, Sunninghill,  
Sandton, 2157  
P.O. Box 521058, Saxonwold, 2132



**Johannesburg**  
Tel: Telkom: +27 (0) 11 770-6000  
Call Centre: +27 (0) 860-932-273

[www.medikredit.co.za](http://www.medikredit.co.za)